Xenon Pharmaceuticals Inc. financial data

Symbol
XENE on Nasdaq
Location
Burnaby
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 03 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1569% % -37%
Debt-to-equity 6% % 52%
Return On Equity -46% % -87%
Return On Assets -43% % -83%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77,275,005 shares 1.4%
Common Stock, Shares, Outstanding 77,120,168 shares 1.7%
Entity Public Float $2,946,200,000 USD 21%
Common Stock, Value, Issued $1,475,371,000 USD 2.3%
Weighted Average Number of Shares Outstanding, Basic 79,247,976 shares 1.7%
Weighted Average Number of Shares Outstanding, Diluted 79,247,976 shares 1.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $272,711,000 USD 42%
General and Administrative Expense $75,569,000 USD 19%
Operating Income (Loss) $340,780,000 USD -33%
Nonoperating Income (Expense) $31,076,000 USD -25%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $309,704,000 USD -45%
Income Tax Expense (Benefit) $3,370,000 USD -656%
Net Income (Loss) Attributable to Parent $306,334,000 USD -44%
Earnings Per Share, Basic -3 USD/shares -37%
Earnings Per Share, Diluted -3 USD/shares -37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $104,514,000 USD 19%
Marketable Securities, Current $357,754,000 USD -37%
Accounts Receivable, after Allowance for Credit Loss, Current $1,469,000 USD 68%
Assets, Current $480,137,000 USD -27%
Deferred Income Tax Assets, Net $11,750,000 USD 1015%
Property, Plant and Equipment, Net $8,887,000 USD -13%
Operating Lease, Right-of-Use Asset $6,960,000 USD -16%
Assets $607,836,000 USD -27%
Employee-related Liabilities, Current $11,098,000 USD 24%
Liabilities, Current $38,335,000 USD 29%
Operating Lease, Liability, Noncurrent $6,832,000 USD -19%
Other Liabilities, Noncurrent $3,158,000 USD
Liabilities $48,325,000 USD 27%
Accumulated Other Comprehensive Income (Loss), Net of Tax $477,000 USD -64%
Retained Earnings (Accumulated Deficit) $1,140,119,000 USD -37%
Stockholders' Equity Attributable to Parent $559,511,000 USD -30%
Liabilities and Equity $607,836,000 USD -27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $61,652,000 USD -33%
Net Cash Provided by (Used in) Financing Activities $1,151,000 USD
Net Cash Provided by (Used in) Investing Activities $34,510,000 USD
Common Stock, Shares, Issued 77,120,168 shares 1.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $26,055,000 USD 71%
Deferred Tax Assets, Valuation Allowance $266,856,000 USD 24%
Deferred Tax Assets, Gross $278,619,000 USD 28%
Operating Lease, Liability $8,327,000 USD -15%
Payments to Acquire Property, Plant, and Equipment $43,000 USD -77%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $307,193,000 USD -47%
Lessee, Operating Lease, Liability, to be Paid $9,274,000 USD -16%
Operating Lease, Liability, Current $1,495,000 USD 7.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,791,000 USD -1.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,803,000 USD 3.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Deferred Income Tax Expense (Benefit) $1,213,000 USD -401%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $947,000 USD -27%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,091,000 USD -39%
Deferred Tax Assets, Operating Loss Carryforwards $173,352,000 USD 45%
Unrecognized Tax Benefits $10,850,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,141,000 USD 3.4%
Operating Lease, Payments $420,000 USD 2.2%
Deferred Tax Assets, Net of Valuation Allowance $9,666,000 USD 1105%
Share-based Payment Arrangement, Expense $53,191,000 USD 5.4%